Your browser doesn't support javascript.
loading
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Li, Jun; Duran, Mercedes A; Dhanota, Ninjit; Chatila, Walid K; Bettigole, Sarah E; Kwon, John; Sriram, Roshan K; Humphries, Matthew P; Salto-Tellez, Manuel; James, Jacqueline A; Hanna, Matthew G; Melms, Johannes C; Vallabhaneni, Sreeram; Litchfield, Kevin; Usaite, Ieva; Biswas, Dhruva; Bareja, Rohan; Li, Hao Wei; Martin, Maria Laura; Dorsaint, Princesca; Cavallo, Julie-Ann; Li, Peng; Pauli, Chantal; Gottesdiener, Lee; DiPardo, Benjamin J; Hollmann, Travis J; Merghoub, Taha; Wen, Hannah Y; Reis-Filho, Jorge S; Riaz, Nadeem; Su, Shin-San Michael; Kalbasi, Anusha; Vasan, Neil; Powell, Simon N; Wolchok, Jedd D; Elemento, Olivier; Swanton, Charles; Shoushtari, Alexander N; Parkes, Eileen E; Izar, Benjamin; Bakhoum, Samuel F.
Afiliação
  • Li J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Duran MA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Dhanota N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Chatila WK; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bettigole SE; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kwon J; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Sriram RK; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Humphries MP; Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, New York.
  • Salto-Tellez M; Volastra Therapeutics Inc., New York, New York.
  • James JA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hanna MG; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Melms JC; Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Vallabhaneni S; Precision Medicine Centre of Excellence, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom.
  • Litchfield K; Precision Medicine Centre of Excellence, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom.
  • Usaite I; Medical Sciences Division, Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Biswas D; Precision Medicine Centre of Excellence, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom.
  • Bareja R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Li HW; Columbia Center for Translational Immunology, New York, New York.
  • Martin ML; Division of Hematology and Oncology, Columbia University Medical Center, New York, New York.
  • Dorsaint P; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Cavallo JA; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, United Kingdom.
  • Li P; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, United Kingdom.
  • Pauli C; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, United Kingdom.
  • Gottesdiener L; Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • DiPardo BJ; Columbia Center for Translational Immunology, New York, New York.
  • Hollmann TJ; Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Merghoub T; Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Wen HY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Reis-Filho JS; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Riaz N; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Su SM; Institute for Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Kalbasi A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Vasan N; Department of Surgery, University of California, Los Angeles, California.
  • Powell SN; Medical Sciences Division, Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Wolchok JD; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Elemento O; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Swanton C; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Shoushtari AN; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Parkes EE; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Izar B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bakhoum SF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Discov ; 11(5): 1212-1227, 2021 05.
Article em En | MEDLINE | ID: mdl-33372007
Cytosolic DNA is characteristic of chromosomally unstable metastatic cancer cells, resulting in constitutive activation of the cGAS-STING innate immune pathway. How tumors co-opt inflammatory signaling while evading immune surveillance remains unknown. Here, we show that the ectonucleotidase ENPP1 promotes metastasis by selectively degrading extracellular cGAMP, an immune-stimulatory metabolite whose breakdown products include the immune suppressor adenosine. ENPP1 loss suppresses metastasis, restores tumor immune infiltration, and potentiates response to immune checkpoint blockade in a manner dependent on tumor cGAS and host STING. Conversely, overexpression of wild-type ENPP1, but not an enzymatically weakened mutant, promotes migration and metastasis, in part through the generation of extracellular adenosine, and renders otherwise sensitive tumors completely resistant to immunotherapy. In human cancers, ENPP1 expression correlates with reduced immune cell infiltration, increased metastasis, and resistance to anti-PD-1/PD-L1 treatment. Thus, cGAMP hydrolysis by ENPP1 enables chromosomally unstable tumors to transmute cGAS activation into an immune-suppressive pathway. SIGNIFICANCE: Chromosomal instability promotes metastasis by generating chronic tumor inflammation. ENPP1 facilitates metastasis and enables tumor cells to tolerate inflammation by hydrolyzing the immunotransmitter cGAMP, preventing its transfer from cancer cells to immune cells.This article is highlighted in the In This Issue feature, p. 995.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Evasão Tumoral / Metástase Neoplásica / Neoplasias / Nucleotídeos Cíclicos Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Evasão Tumoral / Metástase Neoplásica / Neoplasias / Nucleotídeos Cíclicos Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article
...